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Abstract
Introduction This open-label, randomized, two-period
drug interaction study assessed lisdexamfetamine dimesy-
late (LDX) effects on cytochrome P450 (CYP) enzyme
(CYP1A2, CYP2D6, CYP2C19, and CYP3A) activity.
Methods Thirty healthy volunteers were administered the
Cooperstown cocktail (CYP1A2 [caffeine 200 mg],
CYP2D6 [dextromethorphan 30 mg], CYP2C19 [omepra-
zole 40 mg], and CYP3A [midazolam 0.025 mg/kg] sub-
strates) or Cooperstown cocktail ? oral LDX 70 mg.
Blood samples for pharmacokinetic analysis were collected
pre-dose and serially for 72 h post-dose. Treatment dif-
ferences in the primary endpoints, maximum plasma con-
centration (Cmax) and area under the plasma concentration
versus time curve from 0 to infinity (AUC0–?), were
assessed using geometric mean ratios with 90 % CIs.
Results Geometric least squares (LS) means (without
versus with LDX) for Cmax (ng/mL) were 5370 versus 5246
for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23
versus 35.11 for midazolam, and 677.9 versus 466.9 for
omeprazole; and for AUC0–? (ngh/mL) were 56,207
versus 56,688 for caffeine, 34.85 versus 37.27 for dex-
tromethorphan, 92.07 versus 93.04 for midazolam, and
1428 versus 1499 for omeprazole. Geometric LS mean
ratios were within the standard bioequivalence testing
range, except for omeprazole and dextromethorphan Cmax.
Parent/metabolite Cmax and AUC0–? ratios were similar
between treatments except for dextromethorphan/dextror-
phan AUC0–? ratio, which was lower with LDX. No se-
rious or severe treatment-emergent adverse events were
reported.
Conclusions LDX did not alter CYP1A2, CYP2D6, or
CYP3A activity. A small Cmax reduction for omeprazole
and its metabolite was observed, possibly reflecting an
effect either on the activity of CYP2C19 or omeprazole
absorption.
Key Points
Lisdexamfetamine did not alter the activity of the
CYP1A2, CYP2D6, or CYP3A enzymes in healthy
volunteers.
A small Cmax reduction for omeprazole and its
metabolite was observed, possibly reflecting an
effect either on the activity of CYP2C19 or
omeprazole absorption.
1 Introduction
Individuals with attention-deficit/hyperactivity disorder
(ADHD) have high rates of comorbid psychiatric disorders,
including anxiety, major depressive disorder, and disrup-
tive disorders [1–3]. To treat these psychiatric comorbidi-
ties, individuals with ADHD may be prescribed additional
pharmacotherapy.
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In the presence of polypharmacy, there is a potential for
drug–drug interactions. Many of the medications used to
treat these comorbid psychiatric disorders (e.g., antide-
pressants for mood disorders) are known to interact with
cytochrome P450 (CYP) enzymes [4]. For instance, flu-
oxetine strongly inhibits CYP2D6, CYP1A2, and
CYP2C19 activity; similarly, paroxetine strongly inhibits
CYP2D6 activity and nefazodone potently inhibits
CYP3A4 activity [4]. In addition, moderate inhibition of
other CYP enzymes (e.g., CYP2D6, CYP2C9, and
CYP3A4) has been reported with bupropion, duloxetine,
fluoxetine, and fluvoxamine [4].
Psychostimulants, such as amphetamines, are used in the
treatment of ADHD [5]. Because it has been reported that
D-amphetamine is metabolized by CYP2D6 [6], there could
be competition for this isozyme when it is administered
with other CYP2D6 substrates. Therefore, it is important to
determine the effects of stimulant medications on the
pharmacokinetic profiles of selected CYP substrates to
determine if there is a potential for drug–drug interactions.
Lisdexamfetamine dimesylate (LDX), a prodrug of
D-amphetamine [7], is approved in the United States to
treat patients 6 years and older with ADHD and adults with
moderate to severe binge eating disorder [8]. Absorption of
LDX occurs primarily via carrier-mediated transport in the
small intestine [7]. LDX is then metabolized in red blood
cells into D-amphetamine and L-lysine [7].
In an in vitro study in human liver microsomes, LDX did
not produce concentration-dependent or mechanism-based
inhibition of several CYP isozymes, including CYP1A2,
CYP2C19, CYP2D6, and CYP3A4 [9]. Potential interac-
tions of LDX with medications metabolized by CYP en-
zymes have also been examined in two clinical trials in
healthy volunteers [10, 11]. In one open-label study, LDX
administered in combination with venlafaxine extended re-
lease (VXR), which is metabolized by CYP2D6 and
CYP3A4 [4], was associated with small increases in VXR
exposure, small decreases in exposure to the primary VXR
metabolite (O-desmethylvenlafaxine [ODV]), and no
change in composite VXR ? ODV exposure when com-
pared with VXR alone in healthy volunteers [10]. When
LDXwas administered to healthy volunteers in combination
with guanfacine extended release (GXR), which is me-
tabolized by CYP3A4 [12], there were no changes in LDX or
D-amphetamine exposure when compared with LDX alone.
Although a small increase in GXR maximum plasma con-
centration (Cmax) was observed with the LDX ? GXR
combination comparedwith GXR alone, this change was not
considered clinically meaningful [11]. Although these
findings suggest there may be only limited interactions of
LDX with CYP2D6 and CYP3A4 enzyme activity, they are
based on relatively few studies so a more comprehensive
analysis of the effects of LDX on CYP substrates would
provide more insight into the potential for drug–drug inter-
actions with medications metabolized by these systems.
The primary objective of the current study was to assess
the pharmacokinetic profiles of substrates of the CYP1A2
(caffeine), CYP2D6 (dextromethorphan), CYP2C19
(omeprazole), and CYP3A (midazolam) enzymes when
administered as the Cooperstown cocktail alone or in
combination with LDX. A four-drug Cooperstown cocktail
was used to identify potential drug interactions because it
offers the advantages of using commercially available
drugs that have low adverse event (AE) profiles and that
are specific for selected CYP enzymes [13]. In addition, a
secondary objective was to provide tolerability and safety
data for LDX when administered in combination with the
CYP enzyme substrates.
2 Materials and Methods
2.1 Study Design and Treatment
The protocol was approved by the institutional review
board of the study site before the initiation of the study, and
the study was conducted in accordance with the Interna-
tional Conference on Harmonisation and Good Clinical
Practice and with the Declaration of Helsinki. All par-
ticipants provided written informed consent in accordance
with Good Clinical Practice guidelines.
This open-label, randomized, two-period, drug–drug
interaction study was conducted by Clinical Pharmacology
of Miami, Inc (Miami, FL, USA) between December 21,
2012 and February 4, 2013 and consisted of a 28-day
screening phase and two single-dose, 5-day treatment pe-
riods separated by a 7-day washout period between doses.
Before the first treatment period, participants were ran-
domized in a 1:1 ratio to a single administration of either
the Cooperstown cocktail alone, which included substrates
for the CYP1A2 (caffeine), CYP2D6 (dextromethorphan),
CYP2C19 (omeprazole), and CYP3A (midazolam) en-
zymes, or the Cooperstown cocktail in combination with
70 mg LDX. The alternate treatment was administered
during the second treatment period. Randomization oc-
curred immediately before dosing on day 1 of the first
treatment period and was accomplished by assigning a
4-digit randomization number to each participant; the
randomization schedule was produced and held by PRA
International (Lenexa, KS, USA).
Caffeine (200 mg), dextromethorphan (30 mg), and
omeprazole (40 mg) were each administered orally with
240 mL of room temperature water. On days when LDX
was administered, it was also given orally with 240 mL of
room temperature water after omeprazole. All orally ad-
ministered agents were given within a 1-min period, were
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swallowed whole, and administration was confirmed by
mouth check. Midazolam (0.025 mg/kg) was administered
intravenously over a 1-min period within 3 min of the last
orally administered agent; midazolam administration was
immediately followed with a 5-mL normal saline intra-
venous infusion to flush the indwelling catheter.
All participants were required to fast for approximately
10 h before dosing and for another 4 h after dosing. Par-
ticipants were also required to refrain from taking any
fluids 4 h before and 2 h after dosing and were not per-
mitted to lie down for the first 4 h following administra-
tion. A follow-up telephone contact was made
approximately 1 week after the final day of the last treat-
ment period to identify ongoing and/or new AEs and
concomitant medications taken since discharge.
2.2 Participants
Eligible participants were healthy men or nonpregnant,
nonlactating women who were 18–45 years of age, had a
body mass index of 18.5–30.0 kg/m2 at the screening visit,
had hemoglobin values C12 g/dL at screening and at the
start of treatment, and had no clinically significant or
relevant medical history, physical examination, vital signs,
electrocardiogram (ECG), or laboratory evaluations. In
addition, all participants had the ability to understand and
fully comply with the study procedures and to provide
consent.
Participants were excluded from study participation if
they had a current or recurrent comorbid disease that could
affect either the pharmacokinetics of the study drug or the
clinical/laboratory assessments or if they had a history of or
a current medical/psychiatric disorder that required treat-
ment, made them unlikely to fully comply with the study
requirements, or that presented undue risk from the study
drug or procedures. Participants were also excluded if they
had current or a history of significant cardiac problems,
including structural abnormalities, conduction problems,
exercise-related events, clinically significant bradycardia,
cardiomyopathy, transient ischemic attacks, strokes, or
other problems; hypertension, a resting sitting systolic
blood pressure (SBP) [139 mmHg, or a diastolic blood
pressure (DBP) [89 mmHg; a family history of sudden
cardiac death or ventricular arrhythmia; a risk for sui-
cide/suicide ideation or previous suicide attempts; intoler-
ance or hypersensitivity to the study drugs; a history of
alcohol or substance abuse within the past year or con-
sumed excessive amounts of alcohol ([3 units/day for men;
[2 units/day for women); consumed tobacco, another in-
vestigational study drug, or substantially changed their
eating habits within 30 days of the first study dose; rou-
tinely consumed caffeine ([2 units/day) or were prone to
caffeine withdrawal headaches; donated blood within
60 days of the start of the study; or were unable to fast or
follow standardized diet and meal schedules.
2.3 Pharmacokinetic Endpoints
Blood samples for pharmacokinetic analysis were collected
pre-dose and serially for 72 h post-dose. The primary
endpoints were Cmax and area under the plasma concen-
tration versus time curve from 0 to infinity (AUC0–?) for
the parent compounds (caffeine, dextromethorphan,
omeprazole, midazolam) and their metabolites (paraxan-
thine, dextrorphan, 5-hydroxyomeprazole, 1-hydroxymi-
dazolam) when administered in the Cooperstown cocktail
alone or in combination with LDX. Other pharmacokinetic
parameters calculated included time of maximum observed
concentration sampled during dosing interval (tmax), ter-
minal half-life (t), total body clearance for extravascular
administration divided by the fraction of dose absorbed
(CL/F), and volume of distribution associated with the
terminal slope following extravascular administration di-
vided by the fraction of dose absorbed (Vz/F). In addition,
the parent-to-metabolite ratios for Cmax and AUC0–? for
each CYP substrate were calculated for each treatment
regimen, and pharmacokinetic parameters for LDX and
D-amphetamine were assessed.
2.4 Bioanalytical Assays
2.4.1 Cytochrome P450 Substrate Analysis
Concentrations of omeprazole and 5-hydroxyomeprazole,
midazolam and 1-hydroxymidazolam, dextromethorphan
and dextrorphan, and caffeine and paraxanthine were de-
termined using validated liquid chromatography-tandem
mass spectrometry (LC–MS/MS)methods. The LC–MS/MS
system was a Sciex API-4000 mass spectrometer (AB
SCIEX, Framingham, MA) for omeprazole, 5-hydro-
xyomeprazole, midazolam, 10-hydroxymidazolam, caffeine,
and paraxanthine or Sciex API-5000 mass spectrometer for
dextromethorphan and dextrorphan coupled with a Shi-
madzu high-performance liquid chromatography (HPLC)
system (Shimadzu, Kyoto, Japan).
For omeprazole and 5-hydroxyomeprazole, a 50 lL
plasma sample was combined with 50 lL of a deuterated
internal standard (omeprazole-d3 and 5-hydroxyomepra-
zole-d3 dissolved in 50:50 methanol:water) followed by
addition of 600 lL acetonitrile to precipitate the protein.
After centrifugation, the supernatant was diluted with re-
constitution solution (50:50 methanol:water) and 10 lL of
the sample was injected to the LC-MS/MS system. Chro-
matographic separation was achieved on a Phenomenex
Synergi Hydro-RP 80 A˚ 4 lm, 2.0 9 50 mmHPLC column
(Phenomenex, Torrance, CA) with a mobile phase gradient.
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For midazolam and 10-hydroxymidazolam, a 200 lL
plasma sample was combined with 20 lL of a deuterated
internal standard (midazolam-d4 and a-hydroxymidazo-
lam-d4 dissolved in 50:50 methanol:water containing
0.01 N HCl) followed by addition of 1 mL methanol to
precipitate the protein. After centrifugation, the supernatant
was diluted with a reconstitution solution (1 mM ammo-
nium acetate) and 20 lL of the sample was injected to the
LC–MS/MS system. Chromatographic separation was
achieved on an Atlantis T3 3 lm, 2.1 9 50 mm HPLC
column (Waters, Milford, MA) with a mobile phase
gradient.
For dextromethorphan and dextrorphan, a 50 lL plasma
sample was combined with 500 lL of a deuterated internal
standard (dextromethorphan-d3 and dextrorphan-d3 dis-
solved in methanol). After centrifugation, the supernatant
was diluted with a reconstitution solution (0.1 %
formic acid) and 10 lL of the sample was injected to the
LC–MS/MS system. Chromatographic separation was
achieved on a Hypersil GOLD aQ 5 lm, 4.6 9 50 mm
HPLC column (Thermo Scientific, Waltham, MA) with an
isocratic condition.
For caffeine and paraxanthine, a 50 lL plasma sample
was combined with 50 lL internal standard solution (caf-
feine-d3 dissolved in 50:50 methanol water) followed by
addition of 1 mL methanol to precipitate the protein. After
centrifugation, the supernatant was diluted 0.01 N HCl and
10 lL was injected to the LC–MS/MS system. The chro-
matographic separation was achieved on a YMCbasic
3 lm, C-8, 4.6 9 50 mm HPLC column (YMC America,
Allentown, PA) with a mobile phase gradient.
The mass spectrometers were operated in positive
electrospray ionization (ESI) mode. The selected reaction
monitoring transitions were 346.2 m/z ? 198.1 m/z for
omeprazole; 349.2 m/z ? 198.1 m/z for omeprazole-d3;
362.1 m/z ? 213.9 m/z for 5-hydroxyomeprazole; 365.1 m/z
? 213.9 m/z for 5-hydroxyomeprazole-d3; 326.0 m/z
? 291.0 m/z for midazolam; 330.0 m/z ? 294.0 m/z for the
midazolam-d4; 342.0 m/z ? 203.0 m/z for 10-hydroxymi-
dazolam; 346.0 m/z ? 203.0 m/z for a-hydroxymidazo-
lam-d4; 272.2 m/z ? 171.0 m/z for dextromethorphan;
275.2 m/z ? 171.0 m/z for dextromethorphan-d3; 258.2
m/z ? 157.0 m/z for dextrorphan, 261.2 m/z ? 157.0
m/z for dextrorphan-d3; 195.1 m/z ? 138.0 m/z for caf-
feine; 181.0 m/z ? 124.0 m/z for paraxanthine; and
198.1 m/z ? 138.0 m/z for caffeine-d3.
Plasma concentrations were calculated using an 8-point
curve with weighted linear regression. The nominal con-
centrations, based on standards that were prepared in hu-
man plasma, ranged from 1 to 100 ng/mL for omeprazole
(USP, Rockville, MD, USA; Toronto Research Chemicals,
Inc., Toronto, ON, Canada) and 5-hydroxyomeprazole
(Toronto Research Chemicals, Inc., Toronto, ON, Canada),
0.1–100 ng/mL for midazolam (Cerilliant, Round Rock,
TX, USA) and 1-hydroxymidazolam (Cerilliant, Round
Rock, TX, USA; Lipomed, Cambridge, MA, USA),
0.05–50 ng/mL for dextromethorphan (USP, Rockville,
MD, USA; Toronto Research Chemicals, Inc., Toronto,
ON, Canada) and dextrorphan (TLC PharmaChem,
Vaughan, ON, Canada; Cerilliant, Round Rock, TX, USA),
and 20–20,000 ng/mL for caffeine (USP, Rockville, MD,
USA; C/D/N Isotopes Inc., Pointe-Claire, QC, Canada) and
paraxanthine (Toronto Research Chemicals, Inc., Toronto,
ON, Canada). Lower limits of quantification were 1 ng/mL
for omeprazole and 5-hydroxyomeprazole, 0.1 ng/mL for
midazolam and 1-hydroxymidazolam, 0.05 ng/mL for
dextromethorphan and dextrorphan, and 20 ng/mL for
caffeine and paraxanthine. Quality-control samples
(omeprazole and 5-hydroxyomeprazole: 3, 300, 750, and
7500 ng/mL; midazolam and 1-hydroxymidazolam: 0.3,
18, and 78 ng/mL; dextromethorphan and dextrorphan:
0.15, 4, and 39 ng/mL; caffeine and paraxanthine: 60,
7900, and 15,800 ng/mL) were prepared in separate
batches and stored at –20 C. Supplemental Table 1 (see
electronic supplementary material) summarizes the per-
formance characteristics of all the assays.
2.4.2 Lisdexamfetamine and D-Amphetamine Analysis
Concentrations of LDX and D-amphetamine were deter-
mined using a validated LC–MS/MS method. The
LC–MS/MS system was a Sciex API-4000 mass spec-
trometer coupled with a Shimadzu HPLC system. The
selected reaction monitoring transitions were 136.1 ?
119.1 m/z for amphetamine, 141.1? 124.1 m/z for am-
phetamine-d5 internal standard, 264.2 ? 84.2 m/z for lis-
dexamfetamine, and 268.2 ? 88.2 m/z for lisdexamfetamine-
d4 internal standard.
A 100-lL plasma sample was combined with 50 lL of
the internal standard; proteins were precipitated by adding
500 lL of a chilled acetonitrile:formic acid (100:5; volume
to volume) solution. After vortexing and centrifugation, the
supernatant was then added to 300 lL of the reconstitution
solution. Plasma concentrations of LDX and D-am-
phetamine were calculated using an 8-point curve with
weighted linear regression. The nominal concentrations,
based on standards that were prepared in human plasma,
ranged from 1 to 100 ng/mL for LDX (Cerilliant, Round
Rock, TX, USA; Alsachim, Illkirch-Graffenstaden, France)
and from 2 to 200 ng/mL for D-amphetamine (Cerilliant,
Round Rock, TX, USA). Lower limits of quantification
were 1 ng/mL for LDX and 2 ng/mL for D-amphetamine.
Quality-control samples for LDX (3, 20, 80, and
100 ng/mL) and D-amphetamine (6, 40, 160, and
200 ng/mL) were prepared and stored at -20 C before the
start of the analysis. Supplemental Table 1 (see electronic
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supplementary material) summarizes the performance
characteristics of the assays.
2.5 Safety and Tolerability Endpoints
Safety and tolerability endpoints included assessments of
vital signs, 12-lead ECGs, physical examinations, clinical
safety laboratory tests, and AEs. Participant-reported and
investigator-observed AEs were recorded at screening, on
each day during the two treatment periods, and at follow-
up. AEs were classified according to severity and their
relationship to the study drug. Vital signs were assessed at
screening, on day -1 of each treatment period, at 30 min
pre-dose and 2, 4, 8, and 12 h post-dose on day 1 of each
period, and on days 2 (i.e., 24 h post-dose), 3 (i.e., 48 h
post-dose), and 4 (i.e., 72 h post-dose) of each treatment
period. Physical and clinical laboratory examinations were
assessed at screening, on day -1 of each treatment period,
and on day 4 of period 2; ECGs were assessed at screening,
on days -1 and 1 of each treatment period, and on day 4 of
period 2.
2.6 Data Presentation and Statistical Analyses
The sample size was estimated to determine equivalence
between the two regimens for each pharmacokinetic pa-
rameter for each substrate in the Cooperstown cocktail. For
a true mean ratio of 0.95, it was estimated that 24 par-
ticipants needed to complete the study to achieve 85 %
power and a 1-sided a of 0.05 (corresponding to 90 % CI).
All pharmacokinetic analyses were conducted using
WinNonlin Phoenix version 6.3 or higher (Pharsight Corp.,
Mountain View, CA) in the pharmacokinetic analysis set,
which consisted of all participants in the safety analysis set
for whom the primary pharmacokinetic data were consid-
ered sufficient and interpretable. Analysis of variance, with
period and treatment regimen as fixed effects and par-
ticipant nested within sequence as a random effect, was
used to compare the means of log-transformed Cmax and
AUC0–? between treatment regimens for each analyte. To
assess treatment effect magnitude for Cmax and AUC0–?,
geometric mean ratios and 90 % CIs were calculated.
Consistent with guidelines of the Food and Drug Admin-
istration for drug–drug interaction studies [14], bioe-
quivalence test rules were utilized to determine if the 90 %
CI of the geometric mean ratio was within the interval of
0.80–1.25. Treatments were considered equivalent, and
thus no interaction was concluded, if the 90 % CI of the
geometric mean ratio was within the interval of 0.80–1.25.
If the 90 % CI was not wholly contained within the interval
of 0.80–1.25, equivalence was not concluded and a drug
interaction could not be excluded. Descriptive statistics
were also determined for all pharmacokinetic parameters
for each analyte under both treatment regimens. The safety
analysis set included participants who received one or more
doses of study drug and had one or more post-dose safety
assessments. Safety endpoints were summarized using de-
scriptive statistics.
3 Results
3.1 Participant Disposition and Demographics
A total of 30 participants were enrolled and randomized
(15 participants were randomized to receive Cooperstown
cocktail as the initial treatment; 15 were randomized to
receive Cooperstown cocktail ? LDX as the initial treat-
ment); 29 participants completed the study. All 30 par-
ticipants (15 per group) were included in the randomized,
pharmacokinetic, and safety analysis sets; one participant
who received the Cooperstown cocktail as the initial
treatment discontinued before completing the study (pri-
mary reason: ‘‘withdrawal by participant’’).
Overall, the mean ± SD age of participants was
35.6 ± 7.91 years; the majority were White (26/30;
86.7 %) and men (18/30; 60.0 %). Participant demo-
graphics by treatment regimen are summarized in Supple-
mental Table 2 (see electronic supplementary material).
3.2 Pharmacokinetic Endpoints
Figure 1 depicts the mean ± SD plasma concentrations
over time by treatment regimen for the parent substrates
and their primary metabolites. Table 1 presents descriptive
statistics for pharmacokinetic parameters by treatment
regimen for each CYP substrate, its respective metabolite,
and LDX and D-amphetamine.
Geometric least squares (LS) means for Cmax and
AUC0–? for each treatment and the ratios between treat-
ments are summarized in Table 2. The geometric LS mean
ratios for AUC0–? for all treatments were fully contained
within the 80–125 % range. Geometric LS mean ratios for
Cmax for midazolam, caffeine, and their metabolites were
also fully contained within the 80–125 % range. The upper
90 % CI for the Cmax geometric LS mean ratio was outside
the 80–125 % range for dextromethorphan, but the 90 %
CIs were within the accepted range for dextrorphan. For
omeprazole and 5-hydroxyomeprazole, the geometric LS
mean ratios were below the lower limit of the 80–125 %
range.
The mean ± SD parent to metabolite ratios for Cmax and
AUC0–? were similar between treatments (Table 2), with
the exception of dextromethorphan to dextrorphan for
AUC0–?, which was lower when LDX was administered
with the Cooperstown cocktail. Upon further examination
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of the dextromethorphan to dextrorphan ratio, it was ob-
served that five participants had substantially higher ratios
for both Cmax and AUC0–?, which skewed the mean values
for these parameters. Between treatment regimens,
geometric mean values for the dextromethorphan to dex-
trorphan ratio for Cmax (Cooperstown cocktail alone:
0.9588; Cooperstown cocktail ? LDX: 1.2521) and
AUC0–? (Cooperstown cocktail alone: 1.7023; Cooperstown
cocktail ? LDX: 1.8868) were similar.
3.3 Safety and Tolerability Endpoints
The frequency of treatment-emergent AEs (TEAEs) is
summarized in Supplemental Table 3 (see electronic sup-
plementary material). All TEAEs were mild in severity and
considered related to the study drug (any TEAEs, n [%]:
Cooperstown cocktail alone, 18 [60.0]; Cooperstown
cocktail ? LDX, 26 [89.7]). There were no serious or
severe TEAEs, no discontinuations due to TEAEs, and no
deaths reported during the study. Supplemental Table 3
(see electronic supplementary material) shows the fre-
quency of TEAEs reported by C5 % of participants in ei-
ther treatment group. With the Cooperstown cocktail alone,
the most frequent TEAEs (n [%]) were somnolence (13
[43.3]) and dizziness (4 [13.3]); with the Cooperstown
cocktail ? LDX, the most frequent TEAEs included in-
somnia (12 [41.4]), somnolence (10 [34.5]), dry mouth (9
[31.0]), increased blood pressure (8 [27.6]), tachycardia
and dizziness (both 5 [17.2]), decreased appetite and
euphoric mood (both 4 [13.8]), nausea, anxiety, and de-
pressed mood (each 3 [10.3]).
Supplemental Table 4 (see electronic supplementary
material) summarizes mean ± SD changes from baseline
for vital sign assessments. SBP, DBP, and pulse rate in-
creased more with the Cooperstown cocktail ? LDX
compared with the Cooperstown cocktail alone at 4, 8,
and 12 h post-dose. Mean ± SD SBP (Cooperstown
cocktail alone: 2.6 ± 7.76; Cooperstown cocktail ? LDX:
16.9 ± 12.57) and DBP (Cooperstown cocktail alone:
1.8 ± 7.71; Cooperstown cocktail ? LDX: 10.6 ± 10.33)
Fig. 1 Mean ± SD plasma concentrations for a omeprazole and
5-hydroxyomeprazole, b midazolam and 1-hydroxymidazolam, c dex-
tromethorphan and dextrorphan, and d caffeine and paraxanthine by
treatment regimen, pharmacokinetic analysis set. Lower limits of
quantification: omeprazole and 5-hydroxyomeprazole (1 ng/mL),
midazolam and 1-hydroxymidazolam (0.1 ng/mL), dextromethor-
phan and dextrorphan (0.05 ng/mL), caffeine and paraxanthine
(20 ng/mL). LDX lisdexamfetamine dimesylate
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changes from baseline peaked at 8 h post-dose; changes
were similar between treatments at 24 h post-dose.
Mean ± SD increases from baseline for pulse rate peaked
at 12 h post-dose (Cooperstown cocktail alone: 3.7 ± 8.37;
Cooperstown cocktail ? LDX: 23.1 ± 14.63) and re-
mained higher at 24 h post-dose with the Cooperstown
cocktail ? LDX (9.0 ± 12.18) compared with the
Cooperstown cocktail alone (4.5 ± 10.89). Mean ± SD
changes from baseline at day 4 were small for heart rate
(Cooperstown cocktail, 5.3 ± 6.36; Cooperstown cock-
tail ? LDX, 4.9 ± 12.60). No baseline or post-baseline
ECG evaluations were considered clinically relevant.
4 Discussion
This is the first study to simultaneously assess the effects of
LDX on the activity of multiple CYP enzymes in healthy
human volunteers. The results suggest that LDX does not
alter the activity of the CYP1A2, CYP2D6, or CYP3A
enzymes, as evidenced by a lack of LDX effect on
AUC0–? for substrates of these enzymes. As such, LDX is
not expected to alter the pharmacokinetics of concomi-
tantly administered medications that require CYP1A2,
CYP2D6, or CYP3A enzyme activity for their metabolism.
Additionally, coadministration of the Cooperstown cocktail
with LDX did not alter LDX or amphetamine exposure, as
the pharmacokinetic profiles for LDX and D-amphetamine
observed in this study were similar to those observed in
other single-dose LDX studies in healthy adults [15, 16].
These findings are consistent with previously reported
data from an in vitro study, which reported that incubation
of LDX with human liver microsomes was not associated
with concentration-dependent or mechanism-based inhibi-
tion of various CYP enzymes [9]. The data are also gen-
erally consistent with findings in healthy volunteers.
Coadministration of LDX and GXR, which is metabolized
by CYP3A4 [12], produced only small increases in Cmax
for GXR in one study [11]. In another study, coadminis-
tration of LDX with VXR, which is metabolized by
CYP2D6 and CYP3A4 [4], was associated with only minor
increases in VXR exposure, minor decreases in exposure to
ODV, and no change in VXR ? ODV exposure when
compared with VXR alone in healthy volunteers [10].
A small reduction in Cmax for omeprazole and its
metabolite, 5-hydroxyomeprazole, was observed in this
study. This reduction could be the result of changes in
CYP2C19 activity or an effect of LDX on the absorption of
omeprazole. However, the latter is the more likely expla-
nation because the conversion rate from omeprazole to
5-hydroxyomeprazole was unaffected by LDX, as evi-
denced by the omeprazole to 5-hydroxyomeprazole ratio
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Table 2 Geometric LS means and ratios for parent compounds and metabolites, and mean parent to metabolite ratios for Cmax and AUC0–? by
treatment regimen, pharmacokinetic analysis set
Cmax, ng/mL AUC0–?, ngh/mL
Geometric
LS mean
Cooperstown cocktail ? LDX/
Cooperstown cocktail (90 % CI) ratio
Geometric
LS mean
Cooperstown cocktail ? LDX/

























































Mean ± SD Cmax, ng/mL Mean ± SD AUC0–?, ngh/mL
Omeprazole to 5-hydroxyomeprazole ratio
Cooperstown cocktaila 2.0779 ± 1.4317 1.6082 ± 1.2363
Cooperstown cocktail ? LDX 1.8809 ± 1.3421b 1.7008 ± 1.3556c
Midazolam to 1-hydroxymidazolam ratio
Cooperstown cocktaila 13.1254 ± 5.2713 6.9056 ± 2.7659
Cooperstown cocktail ? LDXb 13.8779 ± 6.0046 7.3428 ± 3.2975
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This interpretation is supported by preclinical in vitro data
that reported that LDX was not associated with changes in
CYP2C19 activity [9]. Although a previously published
study in healthy adults reported that combined adminis-
tration of omeprazole with LDX or mixed amphetamine
salts–extended release (MAS-XR) did not significantly al-
ter total amphetamine exposure from LDX or MAS-XR
[17], omeprazole pharmacokinetic parameters were not
assessed in this earlier study. Therefore, it is not known
whether coadministration of LDX ? omeprazole was as-
sociated with alterations in omeprazole pharmacokinetic
parameters in that study.
The pattern of TEAEs with LDX (i.e., insomnia, dry
mouth, increased blood pressure, and tachycardia) in this
study was generally consistent with a previously reported
LDX profile in healthy volunteers [10]. No serious or
severe TEAEs or study discontinuations due to TEAEs
were reported in this study. Changes in vital signs and ECG
assessments were also generally consistent with other
studies in healthy adults [10, 15].
Several limitations of this study should be noted in re-
gard to interpretation of these findings. First, it is important
to note that only single doses of LDX and each CYP
substrate in the Cooperstown cocktail were used in this
study. As such, it is unclear if the use of higher doses of the
CYP substrates, which are more likely to saturate CYP
systems, may alter these findings or if repeated dosing
would influence the results. Third, this study did not assess
the effects of strong CYP inhibitors on the pharmacokinetic
profile of LDX, so it is unclear how coadministration of
these compounds would influence the pharmacokinetics of
LDX. However, no changes in LDX or D-amphetamine
exposure were observed in healthy volunteers after the
coadministration of VXR, which is not a typical strong
inhibitor of CYP2D6 but is metabolized by CYP2D6 [4]
and LDX [10]. Finally, findings related to safety and tol-
erability from this phase I study should be interpreted with
caution because of the small sample size.
5 Conclusions
In summary, at the doses tested in this study, LDX did not
alter the activity of the CYP1A2, CYP2D6, or CYP3A
enzymes in healthy volunteers. This suggests that drug
interactions with medications that are metabolized by these
enzymes would not be expected when administered in
conjunction with LDX. This is of particular importance
in situations where individuals with ADHD are treated for
comorbid conditions, including psychiatric disorders. A
small Cmax reduction for omeprazole and its metabolite was
observed when LDX was administered with the
Cooperstown cocktail, which may be an effect on absorp-
tion of omeprazole. Although an effect of LDX on
CYP2C19 is likely to be minimal, further investigation
may be warranted to more fully explore the impact of LDX
on CYP2C19 activity.
Acknowledgments and conflicts of interest Shire Development
LLC (Wayne, PA) provided funding to Complete Healthcare Com-
munications, Inc. (CHC; Chadds Ford, PA) for support in writing and
editing this manuscript. Under the direction of the authors, Stefan
Kolata, PhD, and Craig Slawecki, PhD, full-time employees of
Complete Healthcare Communications (Chadds Ford, PA), provided
writing and formatting assistance for this manuscript. Brian Scheck-
ner, PharmD, and Phillip Wang, PhD, MBA, of Shire also reviewed
and edited the manuscript for scientific accuracy. James Ermer, Mary
Corcoran, and Patrick Martin are employees of Shire and hold stock
and/or options in Shire.
Table 2 continued
Mean ± SD Cmax, ng/mL Mean ± SD AUC0–?, ngh/mL
Dextromethorphan to dextrorphan ratio
Cooperstown cocktail 19.6953 ± 45.9325a 34.3259 ± 82.8729b
Cooperstown cocktail ? LDX 18.9546 ± 43.0244b 21.8684 ± 47.5228d
Caffeine to paraxanthine ratio
Cooperstown cocktail 3.6489 ± 1.1012a 1.5256 ± 0.3902e
Cooperstown cocktail ? LDX 3.75 ± 1.7019b 1.6297 ± 0.3875f
AUC0–? area under the plasma concentration versus time curve extrapolated to infinity, calculated using the observed value of the last nonzero
concentration, Cmax maximum plasma concentration, LDX lisdexamfetamine dimesylate, LS least squares
a n = 30
b n = 29
c n = 22
d n = 28
e n = 18
f n = 26
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